Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Gyeonggi-do
Clinical trial register · South Korea

Clinical Trials in Gyeonggi-do, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hoffmann-La Roche23 Janssen Research & Development, LLC22 AstraZeneca22 GlaxoSmithKline10 Novartis Pharmaceuticals8
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Gyeonggi-do

213 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)
NCT07521670Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic, Papillary Thyroid Carcinoma
DrugSacituzumab tirumotecan
National Cancer Centre, Singapore
Phase 2
68
Gyeonggi-do, Seoul
2026-11
Not yet open
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
NCT07730840Ischemic Stroke, Transient Ischemic Attack
DrugZastaprazan
Asan Medical Center
Phase 3
984
Daejeon, Gwangju, Gyeonggi-do, Incheon, Jeju City, Jeonju, Seoul
2026-10-15
Recruiting
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
NCT07473700Hypertension, Pulmonary, Lung Diseases, Interstitial
Tectonic Operating Company, Inc.
Phase 2
25
Gyeonggi-do, Seoul
2026-10
Recruiting
AstraZeneca
Phase 3
950
Busan, Daegu, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul, Yangsan
2026-09-16
Recruiting
GlaxoSmithKline
Phase 3
684
Seoul, Gyeonggi-do
2026-09-01
Not yet open
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT07325214Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer
IMGT Co., Ltd.
Not applicable
360
Gyeonggi-do, Seoul
2026-09
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon, Seongbuk-Gu, Seoul
2026-08-24
Recruiting
Guerbet
Phase 3
315
Seoul, Gyeonggi-do
2026-07-28
Recruiting
Seyoung Shin
Observational
300
Gyeonggi-do
2026-07-24
Recruiting
AstraZeneca
Phase 3
600
Bucheon-si, Gyeonggi-do, Jongno-gu, Junggu, Seoul
2026-07-08
Recruiting
AstraZeneca
Phase 3
2,000
Goyang-si, Guri-si, Gwangju, Gyeonggi-do, Seoul, Yangsan
2026-07-06
Recruiting
AstraZeneca
Phase 3
4,500
Busan, Daegu, Goyang-si, Gyeonggi-do, Incheon, Jongno-gu, Seoul, Suwon
2026-06-29
Recruiting
GlaxoSmithKline
Phase 3
450
Seoul, Gyeonggi-do, Suwon Kyunggi-do
2026-06-18
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Goyang-si, Gyeonggi-do, Hwasun, Seoul
2026-05-31
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Seongnam-si, Daegu, Goyang-si, Gyeonggi-do, Seoul
2026-05-21
Recruiting
MetaFines
Phase 2
135
Seoul, Gyeonggi-do
2026-05-08
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 3
118
Gyeonggi-do
2026-04-13
Recruiting
Yuhan Corporation
Phase 2
150
Gyeonggi-do, Daegu, Seoul, Yangsan, Incheon
2026-03-26
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Seongnam-si, Daejeon, Gangwon-do, Gwangju, Gyeonggi-do, Seoul
2026-03-23
Recruiting
Hanmi Pharmaceutical Company Limited
Observational
3,500
Gyeonggi-do
2026-03-19
Recruiting
Samsung Medical Center
Not applicable
2,100
Seoul, Busan, Changwon, Daegu, Gwangju, Gwangmyeong, Gyeonggi-do, Iksan
2026-03-18
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Daegu, Seongnam-si, Daejeon, Gwangju, Gyeonggi-do, Incheon, Seoul
2026-03-16
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Seongnam-si, Hwasun, Gyeonggi-do, Seoul
2026-03-12
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Busan, Gwangju, Gyeonggi-do, Seoul, Suwon
2026-03-05
Recruiting
CKD Bio Corporation
Not applicable
60
Gyeonggi-do, Seoul
2026-02-23
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
Gyeonggi-do, Seoul
2026-01-28
By invitation
Immunovant Sciences GmbH
Phase 2
372
Daegu, Gyeonggi-do
2026-01-26
Recruiting
FutureChem
Phase 3
114
Gyeonggi-do, Seoul, Suwon
2026-01-26
Recruiting
STCube, Inc.
Phase 2
62
Gyeonggi-do, Seoul
2026-01-10
Recruiting
Seoul National University Bundang Hospital
Not applicable
28
Gyeonggi-do
2026-01-06
Recruiting
Hoffmann-La Roche
Phase 3
250
Daegu, Gyeonggi-do, Seoul
2025-11-27
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Ansan-si, Cheonan, Gyeonggi-do, Incheon, Seoul
2025-11-24
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Busan, Gwangju, Gyeonggi-do, Incheon, Seongnam-si, Seoul
2025-11-12
Recruiting
Seyoung Shin
Observational
70
Gyeonggi-do
2025-11-01
Recruiting
Myungmoon Pharma. Co. Ltd.
Phase 4
358
Ansan, Suwon, Busan, Gyeonggi-do, Incheon, Seoul
2025-08-29
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
45
Wŏnju, Gyeonggi-do, Seoul, Cheonan, Daegu
2025-08-28
Recruiting
GlaxoSmithKline
Phase 3
420
Changwon, Cheongju Chungcheongbuk-do, Daegu, Gyeonggi-do, Seongnam-si Gyeonggi-do, Seoul, Suwon Gyeonggi-do, Ulsan
2025-08-11
Recruiting
Myungmoon Pharma. Co. Ltd.
Phase 4
484
Ansan, Bucheon-si, Suwon, Busan, Daegu, Gyeonggi-do, Incheon, Seoul
2025-07-28
Recruiting
Asan Medical Center
Phase 4
2,340
Seoul, Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon
2025-07-10
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Gwangju, Gyeonggi-do, Incheon, Namdong-gu, Seongnam-si, Seoul, Suwon
2025-07-02
Active, closed
Calluna Pharma AS
Phase 2
150
Suwon, Gyeonggi-do, Seoul
2025-06-20
Active, closed
Eisai Korea Inc.
Phase 4
94
Busan, Daegu, Daejeon, Gyeonggi-do, Gyeongnam, Jungnam, Seoul
2025-06-11
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
Gyeonggi-do, Seoul
2025-06-10
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Daejeon, Goyang-si, Gyeonggi-do, Seoul
2025-06-04
Recruiting
Regeneron Pharmaceuticals
Phase 2
297
Gyeonggi-do, Seongnam-si, Incheon, Daegu, Seoul
2025-05-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Gyeonggi-do, Daegu, Seoul
2025-05-22
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Gyeonggi-do, Seoul
2025-05-19
Recruiting
AstraZeneca
Phase 3
1,220
Busan, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul
2025-05-06
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Gyeonggi-do, Cheongju-si, Hwasun, Seoul
2025-05-06
Recruiting
Post Marketing Study on Pluvicto in Korea
NCT06514521Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals
Observational
278
Seongnam-si, Suwon, Busan, Gyeonggi-do, Seoul, Jeollanam
2025-04-18
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Seoul, Gyeonggi-do
2025-04-11
Recruiting
Comparison of Intensive Versus Standard Care & Education for Dyslipidemia in Hypertension and Diabetes Patients
NCT07045623Hypertension, Diabetes Mellitus, Dyslipidemia, Primary Prevention
Saint Vincent's Hospital, Korea
Not applicable
348
Gyeonggi-do
2025-04-01
Recruiting
Yong Wha Moon
Not applicable
6
Gyeonggi-do
2025-04-01
Recruiting
Long-term Follow up Local Registry Study of Kymriah in South Korea
NCT06785818B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Novartis Pharmaceuticals
Observational
500
Bundang Gu, Seongnam-si, Gyeonggi-do, Incheon, Seoul, Busan, Jeollanam, Ulsan
2025-03-12
Recruiting
AstraZeneca
Phase 3
840
Daegu, Goyang-si, Gyeonggi-do, Jeonnam, Seoul
2025-03-01
Not yet open
Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry
NCT06843421Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiovascular Diseases
Korea University
Observational
6,000
Gyeonggi-do, Yongin, Seoul, Gangwon-do, Suwon
2025-03-01
By invitation
Genoss Co., Ltd.
Not applicable
94
Gyeonggi-do
2025-02-19
Active, closed
mAbxience Research S.L.
Phase 3
726
Busan, Gyeonggi-do, Incheon, Seoul
2024-12-30
Active, closed
GlaxoSmithKline
Phase 1/2
14
Daegu, Gyeonggi-do, Seoul
2024-12-13
Recruiting
Yuhan Corporation
Phase 3
60
Gyeonggi-do, Jeollanam-do, Jeollabuk-do, Seoul
2024-12-04
Recruiting
Novo Nordisk A/S
Phase 2
465
Goyang-si, Busan, Gyeonggi-do, Seoul
2024-12-02
Recruiting
AstraZeneca
Phase 3
1,160
Gyeonggi-do, Seoul, Songpa-gu
2024-11-27
By invitation
Novo Nordisk A/S
Observational
840
Goyang-si, Busan, Chungcheongnam-do, Daejeon, Gyeonggi-do, Seoul, Yangsan
2024-11-19
Recruiting
Study of DM5167 in Patients With Advanced Solid Tumors
NCT07101601Advanced Breast Cancer
DIGMBIO
Phase 1
58
Gyeonggi-do, Seoul
2024-10-24
Active, closed
Ipsen
Phase 2
670
Gyeonggi-do, Seoul
2024-10-10
Recruiting
AstraZeneca
Phase 3
744
Busan, Chungcheongbuk-do, Goyang-si, Gyeonggi-do, Jinju, Seoul, Suwon
2024-10-04
Recruiting
GlaxoSmithKline
Phase 1
845
Gyeonggi-do, Seoul
2024-09-30
Recruiting
Stemline Therapeutics, Inc.
Phase 3
4,220
Cheongju-si, Seongnam-si, Incheon, Seoul, Busan, Daegu, Gyeonggi-do, Ulsan
2024-09-27
Active, closed
Hoffmann-La Roche
Phase 3
338
Gyeonggi-do, Incheon, Jeollanam-do, Seongnam-si, Seoul
2024-09-23
Recruiting
AstraZeneca
Phase 3
620
Busan, Gyeonggi-do, Hwasun-gun, Seongnam-si, Seoul
2024-08-12
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Gyeonggi-do, Suwon, Hwasun, Incheon, Seoul, Ulsan
2024-07-16
Recruiting
GlaxoSmithKline
Phase 1
675
Gyeonggi-do, Seoul
2024-07-02
Recruiting
Myeloid Therapeutics
Phase 1
70
Busan, Gyeonggi-do, Seoul
2024-07-01
Recruiting
Real-World Treatment Study of Koselugo (Selumetinib)
NCT06360406Neurofibromatosis 1, Neurofibroma, Plexiform
AstraZeneca
Observational
200
Busan, Chungcheongbuk-do, Daejeon, Gyeonggi-do, Incheon, Jeonnam, Seoul, Wŏnju
2024-06-15
Recruiting
Eli Lilly and Company
Phase 3
510
Busan, Gyeonggi-do, Pusan, Seongnam-si, Seoul, Suwon
2024-04-29
Active, closed
EverEx Inc.
Not applicable
216
Goyang-si, Guri-si, Gyeonggi-do, Seongnam-si, Junggu, Dongjak, Gangdong, Seocho
2024-04-26
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Chungcheongbuk Do, Gyeonggi-do, Jeollanam-do, Seoul
2024-04-18
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Chungcheongbuk Do, Daegu, Gyeonggi-do, Jeollanam-do, Seoul, Yangsan
2024-04-09
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Anyang-si, Busan, Deagu, Gwangju, Gyeonggi-do, Seoul, Suwon
2024-03-29
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Busan, Daegu, Gyeonggi-do, Incheon, Seoul
2024-03-13
Active, closed
AstraZeneca
Phase 3
594
Gyeonggi-do, Seoul
2024-03-04
Recruiting
Novartis Pharmaceuticals
Phase 3
1,400
Bundang Gu, Gyeonggi-do, Seoul, Incheon, Seongnam Gyeonggi
2024-02-28
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Daegu, Gyeonggi-do, Seongnam, Seoul
2024-02-26
Recruiting
Wonju Severance Christian Hospital
Not applicable
588
Gwangju, Wŏnju, Gyeonggi-do, Seoul
2024-02-22
Active, closed
Regeneron Pharmaceuticals
Phase 3
216
Gyeonggi-do, Suwon, Yangsan, Jeonju, Incheon, Busan, Daegu, Seoul
2024-02-15
Recruiting
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor
Frontier Medicines Corporation
Phase 1/2
403
Seoul, Gyeonggi-do
2024-02-12
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Busan, Gyeonggi-do, Seoul, Uijeongbu-si
2024-02-05
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
122
Daejeon, Gyeonggi-do, Seoul
2024-02-01
Recruiting
Vividion Therapeutics, Inc.
Phase 1
280
Daegu, Gyeonggi-do, Seongnam-si, Seoul
2024-01-25
Recruiting
Daiichi Sankyo
Phase 3
50
Daegu, Gyeonggi-do, Jongno-gu, Seoul
2024-01-05
Recruiting
AstraZeneca
Phase 3
1,145
Goyang-si, Gyeonggi-do, Incheon, Seoul, Suwon
2023-12-14
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin
AstraZeneca
Phase 2
226
Gyeonggi-do, Seoul
2023-12-13
Active, closed
Syndax Pharmaceuticals
Phase 2
145
Haeundae, Gwangju, Seoul, Gyeonggi-do, Incheon, Jeonju
2023-12-11
Active, closed
DeepQure Inc.
Not applicable
10
Jeonam, Gyeonggi-do, Seoul
2023-12-04
Recruiting
Ilsan Cha hospital
Observational
500
Gyeonggi-do, Seoul
2023-12-01
Active, closed
Cellid Co., Ltd.
Phase 3
4,000
Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon, Seoul
2023-11-27
Recruiting
LeonaBio
Phase 3
600
Gyeonggi-do, Jeollanam-do, Seoul
2023-10-31
Active, closed
Genentech, Inc.
Phase 2
260
Goyang-si, Gyeonggi-do, Seocho, Seongnam-si, Seoul, Songpa-gu
2023-10-18
Active, closed
Yuhan Corporation
Phase 4
198
Wŏnju, Seoul, Busan, Daejeon, Gwangju, Gyeonggi-do, Incheon
2023-10-18
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Ansan-si, Gwangju, Gyeonggi-do, Seoul
2023-10-12
Recruiting
AstraZeneca
Phase 3
800
Daegu, Goyang-si, Gyeonggi-do, Seoul
2023-09-22
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Goyang-si, Jongno-gu, Yongsan-gu, Dong-gu, Bucheon-si, Bucheonsi Weonmigu, Busan, Gyeonggi-do
2023-09-14
Active, closed
Hoffmann-La Roche
Phase 3
687
Goyang-si, Gyeonggi-do, Jeollanam-do, Seoul, Ulsan
2023-09-14
Recruiting
Ipsen
Phase 3
276
Bucheon-si, Busan, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Junggu
2023-08-31
Not yet open
National Cancer Center, Korea
Not applicable
203
Busan, Gyeongsang, Seoul, Gyeonggi-do, Changwon
2023-08-17
Active, closed
Erasca, Inc.
Phase 1
86
Busan, Seoul, Goyang-si, Gyeonggi-do
2023-08-17
Active, closed
Hoffmann-La Roche
Phase 3
459
Anyang-si, Bucheon-si, Cheongju-si, Gyeonggi-do, Seongnam-si, Seoul
2023-08-08
Recruiting
GlaxoSmithKline
Phase 3
892
Daegu, Gyeonggi-do, Seoul
2023-08-01
Recruiting
Asciminib RMP Study
NCT05943522Chronic Myeloid Leukemia
Novartis Pharmaceuticals
Observational
600
Wŏnju, Anyang-si, Bucheon-si, Uijeongbu-si, Gyeonggi-do, Incheon, Seoul, Suwon
2023-07-19
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Bucheon-si, Daegu, Gyeonggi-do, Incheon, Jeollabuk-do, Seoul, Wŏnju
2023-06-28
Recruiting
DynamiCure Biotechnology
Phase 1
320
Busan, Gyeonggi-do, Seoul
2023-06-28
Active, closed
AstraZeneca
Phase 3
111
Gyeonggi-do, Seongnam-si, Seoul
2023-06-27
Recruiting
Hoffmann-La Roche
Phase 3
420
Daegu, Goyang-si, Gyeonggi-do, Incheon, Seoul
2023-06-07
Recruiting
Hoffmann-La Roche
Phase 3
100
Goyang-si, Gyeonggi-do, Seongnam-si, Seoul
2023-06-01
Active, closed
Janssen Research & Development, LLC
Phase 2
68
Cheongju-si, Gyeonggi-do, Incheon, Jeollanam-do, Seongnam-si, Seoul
2023-05-18
Recruiting
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
NCT06088121Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Advanced Technology & Communications
Not applicable
180
Incheon, Gwangmyeong, Jeonju, Gwangju, Daegu, Gyeonggi-do, Daejeon, Seoul
2023-05-15
Active, closed
FutureChem
Phase 3
138
Gyeonggi-do, Seoul, Soeul
2023-05-08
Recruiting
MedPacto, Inc.
Phase 1/2
78
Gyeonggi-do, Seoul
2023-05-01
Active, closed
Hoffmann-La Roche
Phase 2
204
Gyeonggi-do, Incheon, Seoul
2023-04-13
Recruiting
Seoul National University Bundang Hospital
Observational
1,240
Daegu, Gyeonggi-do, Hwasun, Ilsan, Jinju, Seongnam-si, Seoul, Yangsan
2023-04-01
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Busan, Cheongju-si, Daegu, Gyeonggi-do, Jeollanam-do, Seoul
2023-03-23
Active, closed
Medipost Co Ltd.
Phase 2
84
Gyeonggi-do, Seoul
2023-03-20
Active, closed
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan·Nab-paclitaxel
Gilead Sciences
Phase 2
192
Cheongju-si, Goyang, Gwangju, Gyeonggi-do, Seogu, Seoul
2023-03-16
Active, closed
AstraZeneca
Phase 2
188
Busan, Cheongju-si, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Seongnam-si, Seoul
2023-03-06
Active, closed
Exelixis
Phase 3
317
Busan, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul
2023-01-01
Active, closed
Hoffmann-La Roche
Phase 3
1,290
Bucheon-si, Daegu, Gyeonggi-do, Seoul, Wŏnju
2022-12-29
Recruiting
Anthos Therapeutics, Inc.
Phase 3
2,500
Anyang-si, Busan, Daegu, Daejeon, Goyang-si, Gwangju, Gyeonggi-do, Seongnam-si
2022-12-27
Recruiting
Gilead Sciences
Phase 3
1,514
Chungcheongnam-do, Daegu, Gyeonggi-do, Seodaemun-gu, Seoul
2022-12-12
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Busan, Gyeonggi-do, Incheon, Jeollanam-do, Jeonju, Seoul
2022-10-13
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Busan, Daegu, Gyeonggi-do, Seoul
2022-09-27
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Busan, Daegu, Gwangju, Gyeonggi-do, Hwaseong-si, Seoul, Suwon, Wŏnju
2022-09-19
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Busan, Daegu, Goyang-si, Gwangju, Gyeonggi-do, Seoul, Suwon
2022-09-13
Active, closed
Exelixis
Phase 3
901
Goyang-si, Gyeonggi-do, Hwasun, Seongnam-si, Seoul
2022-09-07
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 2
256
Daejeon, Gyeonggi-do, Seongnam-si, Seoul
2022-08-17
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Gyeonggi-do, Gyeongsangnam-do, Jeollanam-do, Seongnam-si, Seoul
2022-08-05
Active, closed
AstraZeneca
Phase 3
341
Goyang-si, Gyeonggi-do, Jinju, Seoul, Suwon
2022-08-03
Active, closed
Bausch Health Americas, Inc.
Phase 3
466
Busan, Daegu, Daejeon, Gangwon-do, Goyang-si, Gyeonggi-do, Gyeongsang, Seongnam-si
2022-08-03
Active, closed
PureTech
Phase 2
240
Bucheon-si, Goyang-si, Busan, Daegu, Gwangju, Gyeonggi-do, Incheon, Seoul
2022-07-22
Recruiting
Novartis Pharmaceuticals
Observational
900
Cheonan Si, Daegu, Goyang-si, Suwon, Gyeonggi-do, Seoul, Busan, Daejeon
2022-06-29
Active, closed
Corcept Therapeutics
Phase 3
381
Gyeonggi-do, Seoul
2022-06-29
Active, closed
Celgene
Phase 3
939
Daegu, Gyeonggi-do, Hwasun-gun, Seoul
2022-06-23
Active, closed
ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
NCT05355298Pancreatic Cancer, PDAC, Pancreatic Ductal Adenocarcinoma
Amplia Therapeutics Limited
Phase 1/2
62
Gyeonggi-do, Seoul
2022-05-31
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
83
Busan, Cheongju-si, Gyeonggi-do, Seongnam, Seongnam-si, Seoul
2022-05-30
Recruiting
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
DrugELVN-001
Enliven Therapeutics
Phase 1
250
Jeonju, Daegu, Gyeonggi-do, Hwasun, Seoul
2022-05-22
Active, closed
ARCAGY/ GINECO GROUP
Phase 3
260
Gyeonggi-do, Seoul
2022-04-15
Recruiting
Onconic Therapeutics Inc.
Phase 1/2
71
Gyeonggi-do, Seoul
2022-03-30
Recruiting
ORIC Pharmaceuticals
Phase 1/2
350
Cheongju-si, Goyang-si, Gyeonggi-do, Incheon, Seongnam-si, Seoul
2022-03-10
Recruiting
DualityBio Inc.
Phase 1/2
796
Gyeonggi-do, Seoul
2022-01-31
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Busan, Daegu, Daejeon, Dongdaemun-gu, Goyang-si, Gwangju, Gyeonggi-do, Seoul
2022-01-19
Recruiting
Nuvalent Inc.
Phase 1/2
359
Gyeonggi-do, Seoul
2022-01-04
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Gyeonggi-do, Gyeongsangnam-do, Seoul
2021-11-17
Recruiting
Hallym University Medical Center
Phase 3
976
Gyeonggi-do
2021-11-01
Active, closed
AstraZeneca
Phase 3
454
Cheongju-si, Goyang-si, Gyeonggi-do, Seoul
2021-10-28
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Cheonan-si, Cheongju-si, Gangwon-do, Gyeonggi-do, Incheon, Namdong-Gu, Seongbuk-Gu, Seongnam
2021-08-27
Active, closed
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
NCT04651634Head and Neck Squamous Cell Carcinoma, Oral Mucositis
DrugCCRT
MitoImmune Therapeutics
Phase 2
60
Suwon, Jeonju, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Seoul
2021-06-21
Active, closed
FutureChem
Phase 3
398
Gyeonggi-do, Seoul
2021-04-28
Active, closed
Hoffmann-La Roche
Phase 3
557
Goyang-si, Gyeonggi-do, Seoul
2021-04-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Jeollanam-do, Gyeonggi-do, Songpagu, Daegu, Incheon, Seoul
2021-04-21
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Jinju, Busan, Daegu, Gyeonggi-do, Incheon, Jeonju, Seoul, Ulsan
2021-04-09
Active, closed
ALX Oncology Inc.
Phase 2
189
Cheongju-si, Daegu, Daejeon, Gyeonggi-do, Incheon, Seongnam, Seoul, Suwon
2021-04-02
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Daegu, Gangwon-do, Gyeonggi-do, Seoul
2021-04-01
Active, closed
Hoffmann-La Roche
Phase 2
920
Gyeonggi-do, Seoul
2021-01-18
Active, closed
Galderma R&D
Phase 3
500
Gyeonggi-do, Seoul
2021-01-11
Active, closed
Daiichi Sankyo
Phase 3
605
Cheongju-si, Daegu, Gyeonggi-do, Seongnam-si, Seoul
2020-12-21
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Anyang, Daejeon, Gyeonggi-do, Jeju City, Seongnam-si, Seoul
2020-12-11
Active, closed
GlaxoSmithKline
Phase 2/3
758
Cheongju Chungcheongbuk-do, Daegu, Gyeonggi-do, Pusan, Seongnam-si Gyeonggi-do, Seoul, Suwon Kyunggi-do
2020-12-08
Active, closed
Daiichi Sankyo
Phase 3
1,600
Daegu, Gyeonggi-do, Incheon, Irwon-dong, Seoul, Songpa-gu, Yongsan
2020-12-04
Active, closed
Bayer
Phase 4
654
Seongnam-si, Gyeonggi-do, Seoul
2020-11-09
Active, closed
Hoffmann-La Roche
Phase 1/2
518
Gyeonggi-do, Seoul
2020-11-01
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Busan, Gyeonggi-do, Gyeongsangnam-do, Jeollanam-do, Seongnam-si, Seoul
2020-10-13
Active, closed
Hoffmann-La Roche
Phase 3
992
Cheongju-si, Daegu, Gyeonggi-do, Incheon, Seoul, Ulsan
2020-10-09
Active, closed
GlaxoSmithKline
Phase 3
302
Gyeonggi-do, Hwasun, Inchon, Seoul
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Seongnam-si, Seoul, Suwon
2020-09-23
Active, closed
Polaris Group
Phase 2
100
Hwasun-gun, Seoul, Gyeonggi-do
2020-09-14
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
59
Daegu, Gyeonggi-do, Incheon, Seoul
2020-09-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
Gyeonggi-do, Seongnam-si, Daejeon, Seoul
2020-05-19
Active, closed
GlaxoSmithKline
Phase 3
325
Gyeonggi-do, Hwasun, Incheon, Seongnam-si Gyeonggi-do, Seoul
2020-04-02
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
DrugSacituzumab tirumotecan
Klus Pharma Inc.
Phase 1/2
1,410
Seongnam-si, Busan, Daegu, Goyang-si, Gyeonggi-do, Incheon, Seoul
2020-02-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Gyeonggi-do, Daejeon, Seoul
2020-02-27
Active, closed
Hoffmann-La Roche
Phase 2/3
325
Busan, Daegu, Gyeonggi-do, Seoul
2020-01-29
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
95
Gyeonggi-do, Seongnam-si, Suwon, Pusan, Hwasun, Incheon, Cheongju-si, Busan
2020-01-07
Active, closed
Galderma R&D
Phase 3
1,700
Bucheon-si, Busan, Gyeonggi-do, Incheon, Seoul
2019-12-30
Recruiting
Inhibrx Biosciences, Inc
Phase 1/2
340
Gyeonggi-do, Seoul
2019-12-10
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Ulsan, Gyeonggi-do, Busan, Seoul
2019-11-13
Active, closed
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
DrugZipalertinib
Cullinan Therapeutics Inc.
Phase 1/2
284
Goyang-si, Gyeonggi-do, Incheon, Seoul, Soeul, Suwon
2019-10-31
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Busan, Daegu, Gyeonggi-do, Incheon, Seongnam-si, Seoul, Suwon
2019-09-26
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Seongnam-si, Seoul, Gyeonggi-do, Suwon
2019-08-09
Active, closed
Janssen Research & Development, LLC
Phase 3
2,517
Gwangju, Gyeonggi-do, Seoul
2019-06-11
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine
Astellas Pharma Global Development, Inc.
Phase 2
393
Seongnam-si, Suwon, Daegu, Gyeonggi-do, Seoul
2019-03-15
Active, closed
AstraZeneca
Phase 3
724
Cheongju-si, Goyang-si, Gyeonggi-do, Seoul
2019-03-06
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Seongnam-si, Seoul
2019-01-25
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Seoul, Wŏnju, Bundang Gu, Suwon, Gyeonggi-do, Cheongju-si, Incheon, Seongnam Gyeonggi
2018-12-07
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Daegu, Goyang-si, Gyeonggi-do, Incheon, Jeollanam-do, Jeonju, Seongnam-si, Seoul
2018-11-28
Active, closed
AstraZeneca
Phase 3
1,063
Daegu, Goyang-si, Gyeonggi-do, Incheon, Seoul
2018-11-16
Active, closed
Exelixis
Phase 3
187
Busan, Gyeonggi-do, Seoul
2018-10-05
Active, closed
Hoffmann-La Roche
Phase 3
257
Gyeonggi-do, Incheon, Jeollanam-do, Seoul
2018-08-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Gyeonggi-do, Seoul
2018-04-24
Active, closed
MedImmune LLC
Phase 1
400
Cheongju-si, Gyeonggi-do, Incheon, Seoul
2018-04-24
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Ansan-si, Busan, Daegu, Gyeonggi-do, Hwaseong-si, Seongnam, Seongnam-si, Seoul
2018-04-13
Active, closed
Janssen Research & Development, LLC
Phase 1/2
125
Daejeon, Gwangju, Gyeonggi-do, Seoul, Yangsan
2018-04-05
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Busan, Daejeon, Goyang-si, Gwangju, Gyeonggi-do, Incheon, Seoul, Wŏnju
2018-03-23
Active, closed
Yale University
Phase 2
190
Goyang-si, Gyeonggi-do, Seoul
2018-03-20
Active, closed
Genentech, Inc.
Phase 1
181
Gyeonggi-do, Seoul
2017-11-24
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Gyeonggi-do, Jeollanam-do, Seoul
2017-09-22
Active, closed
Hoffmann-La Roche
Phase 3
382
Gyeonggi-do, Jeollanam-do, Seoul
2017-09-20
Active, closed
Acerta Pharma BV
Phase 3
635
Busan, Gyeonggi-do, Seoul
2017-04-05
Active, closed
Acerta Pharma BV
Phase 3
310
Busan, Daegu, Gyeonggi-do, Incheon, Jeonju, Seoul, Tonggu
2017-02-02
Active, closed
Janssen Biotech, Inc.
Observational
535
Busan, Gyeonggi-do, Seongnam-si, Seoul
2016-12-16
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Buk Gu, Gyeonggi-do, Jeollanam-do, Seoul, Suwon
2015-11-19
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Dongan, Seoul, Anyang-si, Goyang-si, Daegu, Gwangju, Gyeonggi-do, Jeju-do
2013-03-18
Active, closed
Genentech, Inc.
Phase 2
378
Daegu, Gyeonggi-do, Incheon, Seoul
2008-10-16
Active, closed
Janssen Scientific Affairs, LLC
Observational
20,167
Busan, Gyeonggi-do, Seongnam-si, Seoul, Sungnam
2007-06-21
Recruiting
Medtronic
Observational
20,000
Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gyeonggi-do, Jeonju, Seongnam-si
1983-01
Rows per page Showing 1–213 of 213
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/gyeonggi-do

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 213 of those studies with a site in Gyeonggi-do.

How many clinical trials are recruiting in Gyeonggi-do?

97 of the 213 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 5 have not yet opened recruitment, 108 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gyeonggi-do), 213 studies
PhaseStudiesRecruitingShare
Phase 31094451.2%
Phase 2381417.8%
Observational17138%
Phase 1/21587%
Not applicable1275.6%
Phase 11074.7%
Phase 2/3612.8%
Phase 4632.8%

Most active sponsors

Lead sponsors with the most studies (Gyeonggi-do)
Lead sponsorStudiesRecruiting
Hoffmann-La Roche237
AstraZeneca2214
Janssen Research & Development, LLC224
GlaxoSmithKline106
Novartis Pharmaceuticals85
Merck Sharp & Dohme LLC51
Regeneron Pharmaceuticals51
Alexion Pharmaceuticals, Inc.43
Daiichi Sankyo42
Astellas Pharma Global Development, Inc.31
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.